Context Therapeutics Inc. reported its full‑year 2025 operating and financial results, posting a net loss of $36.1 million—an increase from $26.7 million in 2024—while research and development expenses rose to $31.9 million from $22.7 million. Cash and cash equivalents stood at $66.0 million as of December 31, 2025, down from $94.4 million at the end of 2024, giving the company a runway into mid‑2027.
The higher R&D spend was driven by increased costs associated with the CT‑202 program ($4.4 million), the CT‑76 program ($1.3 million), and personnel expenses ($3.3 million). In‑process R&D charges related to the acquisition of CT‑95 and the in‑licensing of CT‑202 also contributed to the 2025 expense.
Despite the larger loss, the company’s cash position remains robust. The $66 million balance is expected to fund operations for roughly 12 quarters, providing a two‑year window to reach key clinical milestones. The company emphasized that the cash runway supports its plan to deliver multiple clinical updates in 2026.
The company’s pipeline remains the focus of its strategy. CEO Martin Lehr said, “We believe 2025 was a year of significant progress for Context as we advanced our pipeline of T cell‑engaging bispecific antibodies for solid tumors. We are on track to provide Phase 1a interim data for our CTIM‑76 trial in June 2026. We are also continuing dose escalation for CT‑95 toward target dose levels and expect to provide Phase 1a interim data for this trial in September 2026. Looking ahead, we anticipate dosing the first patient in our CT‑202 Phase 1 trial in the third quarter of 2026.” He added, “Supported by an expected cash runway extending into mid‑2027, we remain focused on execution and believe we are positioned to deliver multiple clinical updates throughout the remainder of 2026.”
The company remains pre‑revenue, and no revenue figures were disclosed. The announcement is the first new financial disclosure in the past week and is considered a material event for investors, as it provides insight into the company’s financial health and pipeline progress.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.